Aditx Therapeutics Inc (ADTX)

Overview

Aditxt, Inc. is a biotech entity that has dedicated its efforts to the innovation and commercialization of advanced technologies aimed at enhancing health by closely monitoring and effectively modulating immune system functionalities. Initially founded under the name ADiTx Therapeutics, Inc., the corporation underwent a rebranding to Aditxt, Inc. in July 2021, marking a new chapter in its mission towards immune health. With its foundation dating back to 2017 and its central operations based in Richmond, Virginia, Aditxt has not only established itself in the biotechnological landscape but also has solidified collaborative ties, through license agreements, with prestigious institutions like Loma Linda University and Leland Stanford Junior University. These collaborations underscore the company's commitment to pioneering immune modulation and monitoring methodologies for public health betterment.

Products and Services

• AditxtScore

This innovation represents a cornerstone in personal health empowerment, enabling individuals to extensively comprehend, efficaciously manage, and consistently monitor their immune profile. Through this, it provides insights into potential assaults by or against the immune system, equipping individuals with actionable data to fortify their health.

• Apoptotic DNA Immunotherapy

Aditxt is pioneering in the arena of nucleic acid-based technologies with its Apoptotic DNA Immunotherapy. This cutting-edge approach mirrors the body’s natural mechanisms of inducing tolerance towards its tissues. It epitomizes a significant leap forward in how autoimmune diseases and disorders are approached, potentially offering novel avenues for therapy and patient care.

• ADI-100

ADI-100 emerges as a promising therapeutic candidate under Aditxt’s development pipeline aimed at addressing several critical health conditions inclusive of skin grafting challenges, psoriasis, type 1 diabetes, and multiple sclerosis. This breadth of application signifies the potential of ADI-100 to revolutionize treatment paradigms across diverse medical fields.